JP2014515763A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515763A5 JP2014515763A5 JP2014509377A JP2014509377A JP2014515763A5 JP 2014515763 A5 JP2014515763 A5 JP 2014515763A5 JP 2014509377 A JP2014509377 A JP 2014509377A JP 2014509377 A JP2014509377 A JP 2014509377A JP 2014515763 A5 JP2014515763 A5 JP 2014515763A5
- Authority
- JP
- Japan
- Prior art keywords
- stable liquid
- liquid pharmaceutical
- pharmaceutical formulation
- antibody
- humanized antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161481522P | 2011-05-02 | 2011-05-02 | |
| US61/481,522 | 2011-05-02 | ||
| US201161544054P | 2011-10-06 | 2011-10-06 | |
| US61/544,054 | 2011-10-06 | ||
| PCT/US2012/036069 WO2012151247A2 (en) | 2011-05-02 | 2012-05-02 | FORMULATION FOR ANTI-α4β7 ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094129A Division JP6467457B2 (ja) | 2011-05-02 | 2017-05-10 | 抗α４β７抗体のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515763A JP2014515763A (ja) | 2014-07-03 |
| JP2014515763A5 true JP2014515763A5 (enExample) | 2015-06-25 |
| JP6190359B2 JP6190359B2 (ja) | 2017-08-30 |
Family
ID=46147702
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509377A Active JP6190359B2 (ja) | 2011-05-02 | 2012-05-02 | 抗α４β７抗体のための製剤 |
| JP2017094129A Active JP6467457B2 (ja) | 2011-05-02 | 2017-05-10 | 抗α４β７抗体のための製剤 |
| JP2019003265A Active JP6751450B2 (ja) | 2011-05-02 | 2019-01-11 | 抗α４β７抗体のための製剤 |
| JP2020136927A Active JP7107997B2 (ja) | 2011-05-02 | 2020-08-14 | 抗α４β７抗体のための製剤 |
| JP2022112814A Active JP7636651B2 (ja) | 2011-05-02 | 2022-07-14 | 抗α４β７抗体のための製剤 |
| JP2025005609A Pending JP2025061332A (ja) | 2011-05-02 | 2025-01-15 | 抗α４β７抗体のための製剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017094129A Active JP6467457B2 (ja) | 2011-05-02 | 2017-05-10 | 抗α４β７抗体のための製剤 |
| JP2019003265A Active JP6751450B2 (ja) | 2011-05-02 | 2019-01-11 | 抗α４β７抗体のための製剤 |
| JP2020136927A Active JP7107997B2 (ja) | 2011-05-02 | 2020-08-14 | 抗α４β７抗体のための製剤 |
| JP2022112814A Active JP7636651B2 (ja) | 2011-05-02 | 2022-07-14 | 抗α４β７抗体のための製剤 |
| JP2025005609A Pending JP2025061332A (ja) | 2011-05-02 | 2025-01-15 | 抗α４β７抗体のための製剤 |
Country Status (39)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| RS62853B1 (sr) | 2010-01-06 | 2022-02-28 | Takeda Pharmaceuticals Co | Proteini koji vezuju kalikrein plazme |
| PL2624865T3 (pl) * | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
| AU2012204202A1 (en) | 2011-01-06 | 2013-07-11 | Dyax Corp. | Plasma kallikrein binding proteins |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| US10040855B2 (en) * | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AU2012278802B2 (en) | 2011-07-06 | 2015-11-26 | Société des Produits Nestlé S.A. | Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| US9764093B2 (en) * | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
| CA3208188A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Pharmaceutical Company Limited | Anti-plasma kallikrein antibodies |
| CN117717569A (zh) * | 2013-07-05 | 2024-03-19 | 恒星生物群落有限公司 | 口服组合物 |
| BR112016011224A2 (pt) * | 2013-11-29 | 2017-09-19 | Ares Trading Sa | Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc |
| PT3096798T (pt) | 2014-01-21 | 2021-02-25 | Dyax Corp | Proteínas de ligação à calicreína plasmática e seus usos no tratamento de angioedema hereditário |
| AU2015235967B2 (en) | 2014-03-27 | 2020-10-22 | Takeda Pharmaceutical Company Limited | Compositions and methods for treatment of diabetic macular edema |
| MA40592A (fr) | 2014-10-06 | 2016-04-14 | Chemocentryx Inc | Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| MX388043B (es) | 2014-12-03 | 2025-03-19 | Csl Behring Ag | Producto farmacéutico con estabilidad incrementada que comprende inmunoglobulinas. |
| JP2018500553A (ja) * | 2014-12-05 | 2018-01-11 | ネステク ソシエテ アノニム | 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| MA41636A (fr) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | Méthode de traitement de la cholangite sclérosante primitive |
| IL305207A (en) * | 2015-03-30 | 2023-10-01 | Takeda Pharmaceuticals Co | Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| CN116077648A (zh) | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| IL299759A (en) * | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| USD866757S1 (en) | 2016-03-11 | 2019-11-12 | Millennium Pharmaceuticals, Inc. | Autoinjector |
| CA3017743A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| WO2017160700A1 (en) | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Methods of treating or preventing graft versus host disease |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
| US11389533B2 (en) | 2016-06-12 | 2022-07-19 | Takeda Pharmaceutical Company Limited | Method of treating inflammatory bowel disease |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| US20200131251A1 (en) * | 2016-12-23 | 2020-04-30 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| CN108686204A (zh) * | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
| BR112019022268A2 (pt) * | 2017-04-28 | 2020-05-19 | Millennium Pharmaceuticals, Inc. | método para o tratamento de distúrbios pediátricos |
| EP3672994A4 (en) * | 2017-08-25 | 2021-06-02 | Omeros Corporation | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME |
| EP3773694A4 (en) * | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Antibody formulation |
| EP3773696A4 (en) | 2018-04-10 | 2021-12-29 | Dr. Reddy's Laboratories Ltd. | Stable formulations of therapeutic antibody |
| WO2019198099A1 (en) * | 2018-04-10 | 2019-10-17 | Dr. Reddy's Laboratories Limited | Stable antibody formulation |
| EP3843783A1 (en) * | 2018-08-29 | 2021-07-07 | GlaxoSmithKline Intellectual Property Development Limited | Methods of preparing stable liquid therapeutic protein compositions |
| CN118976023A (zh) * | 2019-01-08 | 2024-11-19 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病况的方法 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| MA55735A (fr) * | 2019-04-17 | 2022-02-23 | Millennium Pharm Inc | Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23 |
| JP7753105B2 (ja) * | 2019-06-10 | 2025-10-14 | 武田薬品工業株式会社 | 抗体の精製方法及びその組成物 |
| AU2020364436A1 (en) * | 2019-10-11 | 2022-04-21 | Dr. Reddy's Laboratories Limited | Stable formulation of integrin antibody |
| MX2022008649A (es) | 2020-01-13 | 2022-09-23 | Takeda Pharmaceuticals Co | Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico. |
| TWI800824B (zh) * | 2020-05-08 | 2023-05-01 | 大陸商亘喜生物科技（上海）有限公司 | 一種抗cd19抗體的抗體及其製備和應用 |
| CA3190109A1 (en) * | 2020-07-31 | 2022-02-03 | Genentech, Inc. | Anti-integrin beta7 antibody formulations and devices |
| US20230340131A1 (en) * | 2020-11-12 | 2023-10-26 | Dr. Reddy’S Laboratories Limited | Stable aqueous high concentration formulation of integrin antibody |
| WO2022123603A1 (en) * | 2020-12-09 | 2022-06-16 | Dr. Reddy's Laboratories Limited | Stable aqueous buffer free formulation of an integrin antibody |
| EP4346899A1 (en) * | 2021-06-04 | 2024-04-10 | Polpharma Biologics S.A. | Vedolizumab formulation |
| CN113813377A (zh) * | 2021-09-07 | 2021-12-21 | 杭州远大生物制药有限公司 | 抗α4β7抗体制剂及其应用 |
| EP4456917A1 (en) | 2021-12-27 | 2024-11-06 | Polpharma Biologics S.A. | Vedolizumab formulation |
| US20250326811A1 (en) * | 2022-05-27 | 2025-10-23 | Sonnet BioTherapeutics, Inc. | Il-12-albumin-binding domain fusion protein formulations and methods of use thereof |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
| WO2025041000A1 (en) * | 2023-08-21 | 2025-02-27 | Intas Pharmaceuticals Ltd. | STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY |
| US12134635B1 (en) | 2023-12-29 | 2024-11-05 | Sonnet BioTherapeutics, Inc. | Interleukin 18 (IL-18) variants and fusion proteins comprising same |
| WO2025149974A1 (en) | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| WO2025177055A1 (en) * | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Combination therapy for treating inflammatory bowel disease |
| WO2025177214A1 (en) | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
| WO2026022216A1 (en) * | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| ATE114478T1 (de) | 1987-08-11 | 1994-12-15 | Univ Leland Stanford Junior | Verfahren zur kontrolle der leukozyten- extravasation. |
| US5538724A (en) | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| US5403919A (en) | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5223392A (en) | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| EP0462111A4 (en) | 1988-12-23 | 1992-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Homing sequences and their uses |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL95501A (en) | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| KR100240308B1 (ko) | 1991-03-06 | 2000-01-15 | 플레믹 크리스티안 | 인간화된단클론성항체및혼성단클론성항체 |
| US5665595A (en) | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| ES2103468T3 (es) | 1992-02-12 | 1997-09-16 | Biogen Inc | Tratamiento de la inflamacion intestinal. |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| WO1993023526A1 (en) | 1992-05-21 | 1993-11-25 | Center For Blood Research, Inc. | A NOVEL RECEPTOR FOR α4 INTEGRINS AND METHODS BASED THEREON |
| AU5732694A (en) | 1992-12-01 | 1994-06-22 | Protein Design Labs, Inc. | Humanized antibodies reactive with cd18 |
| WO1994013312A1 (en) | 1992-12-15 | 1994-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
| CA2153692C (en) | 1993-01-12 | 2011-11-08 | Roy R. Lobb | Recombinant anti-vla4 antibody molecules |
| ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
| US6017695A (en) | 1993-03-26 | 2000-01-25 | Becton Dickinson And Company | Nucleic acids encoding human cell adhesion molecule |
| JPH06303990A (ja) | 1993-04-24 | 1994-11-01 | Kanebo Ltd | モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| AU703152B2 (en) | 1994-01-25 | 1999-03-18 | Biogen Ma Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
| US5610281A (en) | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
| GB2292079B (en) | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US5624321A (en) | 1994-12-23 | 1997-04-29 | Snyder; Stephen D. | Spring-actuated swing device |
| JP4205162B2 (ja) | 1995-02-10 | 2009-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 粘膜血管アドレシンおよびその用途 |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6189195B1 (en) | 1995-08-22 | 2001-02-20 | Medrad, Inc. | Manufacture of prefilled syringes |
| US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
| US6015662A (en) | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| CA2385745C (en) * | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| AR038605A1 (es) | 2002-02-25 | 2005-01-19 | Elan Pharm Inc | Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento |
| EP1507756B1 (en) | 2002-05-24 | 2015-07-22 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| DK1798223T4 (da) | 2002-11-18 | 2014-09-22 | Chemocentryx Inc | Arylsulfonamider |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| US6886838B1 (en) | 2003-01-22 | 2005-05-03 | Zimmco | Easy dumping cart |
| CA2517310C (en) | 2003-02-28 | 2015-11-24 | Chugai Seiyaku Kabushiki Kaisha | Stabilized protein-containing formulations comprising a poloxamer |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| HUE058817T2 (hu) | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| FI1850892T4 (fi) | 2005-01-24 | 2023-08-31 | Neula-avusteinen esitäytetyn ruiskun omaava suihkuinjektori | |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| WO2006096461A2 (en) * | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| AU2006316629A1 (en) | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with alpha 4 beta 7 integrin |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| CN101426527A (zh) * | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| US8945564B2 (en) | 2006-04-21 | 2015-02-03 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions |
| EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
| BRPI0721097A2 (pt) * | 2006-12-11 | 2014-07-01 | Hoffmann La Roche | Formulação parenteral de anticorpo abeta |
| US9111016B2 (en) | 2007-07-06 | 2015-08-18 | Stereotaxis, Inc. | Management of live remote medical display |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20100260853A1 (en) * | 2007-12-13 | 2010-10-14 | Amrik Basran | Compositions for pulmonary delivery |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| SG10201402265YA (en) * | 2008-02-07 | 2014-08-28 | Amgen Inc | Stabilized protein compositions |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| EP2315778A2 (en) * | 2008-07-18 | 2011-05-04 | Domantis Limited | Compositions monovalent for cd28 binding and methods of use |
| TWI610936B (zh) * | 2008-10-20 | 2018-01-11 | 艾伯維有限公司 | 使用蛋白質ａ親和性層析進行抗體之分離及純化 |
| EP2408816B1 (en) * | 2009-03-20 | 2019-09-04 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
| WO2010121141A1 (en) * | 2009-04-17 | 2010-10-21 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
| CN101533504A (zh) * | 2009-04-27 | 2009-09-16 | 刘文祥 | 电子医务系统及其装置 |
| RU2560701C2 (ru) * | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| CN107496917B (zh) | 2010-02-26 | 2021-06-11 | 诺沃—诺迪斯克有限公司 | 包含稳定抗体的组合物 |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US10040855B2 (en) | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| MA44864A (fr) | 2016-05-04 | 2019-03-13 | Icahn School Med Mount Sinai | Trithérapie pour le traitement d'une maladie intestinale inflammatoire |
-
2012
- 2012-05-02 US US14/114,835 patent/US10040855B2/en active Active
- 2012-05-02 TW TW106123969A patent/TWI698254B/zh active
- 2012-05-02 EP EP24167554.5A patent/EP4403579B1/en active Active
- 2012-05-02 SI SI201232102T patent/SI4403579T1/sl unknown
- 2012-05-02 KR KR1020237002891A patent/KR20230021758A/ko not_active Ceased
- 2012-05-02 EA EA201391613A patent/EA032625B1/ru not_active IP Right Cessation
- 2012-05-02 WO PCT/US2012/036069 patent/WO2012151247A2/en not_active Ceased
- 2012-05-02 PT PT241675545T patent/PT4403579T/pt unknown
- 2012-05-02 CN CN201280021789.8A patent/CN103533959B/zh active Active
- 2012-05-02 PH PH1/2018/502221A patent/PH12018502221B1/en unknown
- 2012-05-02 PL PL24167554.5T patent/PL4403579T3/pl unknown
- 2012-05-02 AU AU2012250872A patent/AU2012250872B2/en active Active
- 2012-05-02 DK DK12722973.0T patent/DK2704742T3/en active
- 2012-05-02 IL IL274846A patent/IL274846B2/en unknown
- 2012-05-02 HR HRP20171457TT patent/HRP20171457T1/hr unknown
- 2012-05-02 TW TW108104506A patent/TWI723339B/zh active
- 2012-05-02 LT LTEP24167554.5T patent/LT4403579T/lt unknown
- 2012-05-02 CA CA3051418A patent/CA3051418C/en active Active
- 2012-05-02 LT LTEP12722973.0T patent/LT2704742T/lt unknown
- 2012-05-02 MX MX2017007134A patent/MX367097B/es unknown
- 2012-05-02 MY MYPI2013003974A patent/MY188820A/en unknown
- 2012-05-02 SM SM20170515T patent/SMT201700515T1/it unknown
- 2012-05-02 RS RS20260037A patent/RS67634B1/sr unknown
- 2012-05-02 RS RS20171015A patent/RS56429B1/sr unknown
- 2012-05-02 CN CN201711133991.0A patent/CN107998388B/zh active Active
- 2012-05-02 GE GEAP201213302A patent/GEP20186866B/en unknown
- 2012-05-02 KR KR1020177012979A patent/KR101884406B1/ko active Active
- 2012-05-02 KR KR1020217031194A patent/KR102493433B1/ko active Active
- 2012-05-02 KR KR1020257019939A patent/KR20250093426A/ko active Pending
- 2012-05-02 IL IL305583A patent/IL305583B1/en unknown
- 2012-05-02 JP JP2014509377A patent/JP6190359B2/ja active Active
- 2012-05-02 SI SI201231076T patent/SI2704742T1/sl unknown
- 2012-05-02 PE PE2013002433A patent/PE20141672A1/es active IP Right Grant
- 2012-05-02 EP EP24167547.9A patent/EP4378959A3/en active Pending
- 2012-05-02 HU HUE12722973A patent/HUE036664T2/hu unknown
- 2012-05-02 GE GEAP201813302A patent/GEAP201813302A/en unknown
- 2012-05-02 TW TW111148303A patent/TWI832619B/zh active
- 2012-05-02 MX MX2019009244A patent/MX384203B/es unknown
- 2012-05-02 KR KR1020207020503A patent/KR102308938B1/ko active Active
- 2012-05-02 ME MEP-2017-227A patent/ME02858B/me unknown
- 2012-05-02 MX MX2013012725A patent/MX354101B/es active IP Right Grant
- 2012-05-02 CN CN201810453958.4A patent/CN108969469A/zh active Pending
- 2012-05-02 PH PH1/2013/502237A patent/PH12013502237A1/en unknown
- 2012-05-02 HR HRP20260026TT patent/HRP20260026T1/hr unknown
- 2012-05-02 PT PT127229730T patent/PT2704742T/pt unknown
- 2012-05-02 PL PL12722973T patent/PL2704742T3/pl unknown
- 2012-05-02 EP EP24167555.2A patent/EP4438625A3/en active Pending
- 2012-05-02 EP EP17180247.3A patent/EP3311834B1/en active Active
- 2012-05-02 TW TW101115710A patent/TWI638661B/zh active
- 2012-05-02 AR ARP120101540A patent/AR086238A1/es not_active Application Discontinuation
- 2012-05-02 CA CA2834900A patent/CA2834900C/en active Active
- 2012-05-02 KR KR1020137031205A patent/KR101875155B1/ko active Active
- 2012-05-02 TW TW113101357A patent/TWI907924B/zh active
- 2012-05-02 KR KR1020187018702A patent/KR102014512B1/ko active Active
- 2012-05-02 CN CN201810453956.5A patent/CN108969761A/zh active Pending
- 2012-05-02 SG SG2013080940A patent/SG194730A1/en unknown
- 2012-05-02 EP EP12722973.0A patent/EP2704742B1/en not_active Revoked
- 2012-05-02 UY UY0001034054A patent/UY34054A/es not_active Application Discontinuation
- 2012-05-02 DK DK24167554.5T patent/DK4403579T3/da active
- 2012-05-02 KR KR1020197024347A patent/KR102136208B1/ko active Active
- 2012-05-02 FI FIEP24167554.5T patent/FI4403579T3/fi active
- 2012-05-02 TW TW109140548A patent/TWI799757B/zh active
- 2012-05-02 SM SM20260024T patent/SMT202600024T1/it unknown
- 2012-05-02 ES ES12722973.0T patent/ES2646717T3/es active Active
-
2013
- 2013-10-29 CR CR20130556A patent/CR20130556A/es unknown
- 2013-10-29 DO DO2013000252A patent/DOP2013000252A/es unknown
- 2013-10-30 CL CL2013003145A patent/CL2013003145A1/es unknown
- 2013-10-31 ZA ZA2013/08168A patent/ZA201308168B/en unknown
- 2013-10-31 MX MX2021008112A patent/MX2021008112A/es unknown
- 2013-10-31 IL IL229169A patent/IL229169B/en active IP Right Grant
- 2013-11-01 CO CO13259852A patent/CO6801648A2/es unknown
-
2017
- 2017-04-05 CL CL2017000829A patent/CL2017000829A1/es unknown
- 2017-05-10 JP JP2017094129A patent/JP6467457B2/ja active Active
- 2017-06-21 AU AU2017204192A patent/AU2017204192B2/en active Active
- 2017-10-11 CY CY20171101057T patent/CY1119436T1/el unknown
- 2017-10-27 ZA ZA2017/07310A patent/ZA201707310B/en unknown
-
2018
- 2018-05-18 US US15/983,791 patent/US20180327497A1/en not_active Abandoned
- 2018-06-15 US US16/009,865 patent/US20180346578A1/en not_active Abandoned
- 2018-10-12 HK HK18113059.1A patent/HK1253911A1/en unknown
-
2019
- 2019-01-11 JP JP2019003265A patent/JP6751450B2/ja active Active
- 2019-07-17 PH PH12019501662A patent/PH12019501662A1/en unknown
- 2019-08-15 AU AU2019216679A patent/AU2019216679B2/en active Active
-
2020
- 2020-01-26 IL IL272237A patent/IL272237B/en unknown
- 2020-02-11 US US16/787,521 patent/US11560434B2/en active Active
- 2020-06-12 CL CL2020001579A patent/CL2020001579A1/es unknown
- 2020-08-14 JP JP2020136927A patent/JP7107997B2/ja active Active
-
2021
- 2021-04-23 US US17/239,512 patent/US12286479B2/en active Active
- 2021-08-31 AU AU2021225160A patent/AU2021225160B2/en active Active
-
2022
- 2022-02-23 IL IL290848A patent/IL290848A/en unknown
- 2022-02-23 IL IL290849A patent/IL290849A/en unknown
- 2022-06-10 EC ECSENADI202246340A patent/ECSP22046340A/es unknown
- 2022-07-14 JP JP2022112814A patent/JP7636651B2/ja active Active
- 2022-10-13 US US18/046,450 patent/US20230312727A1/en active Pending
-
2023
- 2023-12-04 AU AU2023274233A patent/AU2023274233A1/en active Pending
-
2024
- 2024-10-11 US US18/912,587 patent/US20250034263A1/en active Pending
-
2025
- 2025-01-15 JP JP2025005609A patent/JP2025061332A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515763A5 (enExample) | ||
| JP2014514346A5 (enExample) | ||
| JP2017523187A5 (enExample) | ||
| JP2006522830A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2020518599A5 (enExample) | ||
| JP2017537105A5 (enExample) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| RU2016103079A (ru) | Составы антител и способы | |
| JP2016538277A5 (enExample) | ||
| JP2012021001A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2013533858A5 (enExample) | ||
| JP2013543501A5 (enExample) | ||
| JP2016515124A5 (enExample) | ||
| JP2018521135A (ja) | 免疫調節を使用してがんを処置するための新規手法 | |
| JP2014533279A5 (enExample) | ||
| JP2012102122A5 (enExample) | ||
| JP2014511361A5 (enExample) | ||
| JP2019534891A5 (enExample) | ||
| JP2010500370A5 (enExample) | ||
| JP2015500822A5 (enExample) | ||
| JP2019512472A5 (enExample) | ||
| JP2020502219A5 (enExample) | ||
| JP2019528285A5 (enExample) |